NATCO Pharma Limited (BOM:524816)
817.00
-4.50 (-0.55%)
At close: Nov 20, 2026
NATCO Pharma Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, NATCO Pharma stock has a consensus rating of "Buy" and an average price target of ₹1,002. The average 1-year stock price forecast is 22.66% higher than the current stock price, while the lowest is ₹712.00 (-12.85%) and the highest is ₹1,240 (+51.77%).
Price Target: ₹1,002 (+22.66%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for NATCO Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 2 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Financial Forecast
Revenue This Year
33.65B
from 40.82B
Decreased by -17.56%
Revenue Next Year
37.06B
from 33.65B
Increased by 10.12%
EPS This Year
42.09
from 79.20
Decreased by -46.86%
EPS Next Year
46.92
from 42.09
Increased by 11.49%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.